|
|||||
|
|
||||||
© 2003 American Society for Clinical Oncology
Unusual Abdominal and Pelvic TumorsCASE 2. SPONTANEOUS REGRESSION OF PERITONEAL IMPLANTS IN BORDERLINE OVARIAN TUMOR AFTER SALPINGO-OOPHORECTOMYInstitut Gustave Roussy, Villejuif, France; and Centre Hospitalier Universitaire Bichat, Paris, France
A 49-year-old woman, with a history of right salpingo-oophorectomy for ovarian borderline tumor 20 years previously, underwent a laparoscopic procedure for pelvic pains. A suspicious tumor on the left ovary, with numerous peritoneal implants on the pelvic cavity and a myoma, were found during the laparoscopy. A conversion to laparotomy was performed to carry out a left salpingo-oophorectomy, myomectomy, and peritoneal biopsies. Histologic examinations revealed the presence of serous borderline tumor of the ovary with micropapillary component, positive peritoneal cytology, and noninvasive peritoneal implants (Fig 1
Peritoneal implants from borderline ovarian tumor are defined as invasive or noninvasive depending on the presence or absence of stroma infiltration. The rate of recurrence with invasive disease is 31% in patients with invasive peritoneal implants versus 2% in patients with noninvasive implants.1 Prognosis of patients with noninvasive implants is good. Peritoneal implants are not chemosensitive lesions. The most important therapy is surgery with resection of all macroscopic disease.2 As in patients with ovarian carcinoma, such surgery may involve large resection of the peritoneum with eventually bowel resection in cases of extensive peritoneal implants. Such "debulking" surgery is associated with high morbidity, which could be unacceptable particularly in young patients with noninvasive implants treated conservatively to preserve fertility. Our observation of spontaneous regression of peritoneal implants following resection of the ovarian tumor is exceptional and has important management implications. It could suggest that in young patients with noninvasive implants confirmed by multiple peritoneal biopsies, if the surgery needed to achieve a complete resection of implants would be too aggressive (bowel resection) or unacceptable by the patient, it would be advisable to propose a simple resection of the ovarian tumor with a second look surgery several weeks after this initial operation. The pathogenesis of peritoneal implants is debated: some authors think that peritoneal implants are "metastases" from the ovarian tumor3 whereas others think that peritoneal and ovarian tumors arise independently in response to the same tumorigenic agents.4 A recent important study using clonality testing (based on inactivation of X chromosome) in patients with ovarian borderline tumor and peritoneal implants suggests that peritoneal implants and the ovarian borderline tumor arise independently.5 Our case suggests that the clinical behavior of peritoneal implants is related to the primary ovarian tumor possibly due to the secretion of prosurvival factors. AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The authors indicated no potential conflicts of interest.
REFERENCES
1. Morice P, Camatte S, Rey A, et al: Prognostic factors of patients with advanced stage serous borderline tumor of the ovary. Ann Oncol 14:592598, 2003 2. Gershenson DM: Contemporary treatment of borderline ovarian tumors. Cancer Invest 17:206210, 1999[Medline] 3. Segal GH, Hart WR: Ovarian serous tumors of low malignant potential (serous borderline tumors): The relationship of exophytic surface tumor to peritoneal "implants." Am J Surg Pathol 16:577583, 1992[Medline] 4. Russel P: The pathological assessment of ovarian neoplasms, I: Introduction to the common "epithelial" tumours and analysis of benign "epithelial" tumours. Pathology 11:526, 1979[Medline]
5. Gu J, Roth LM, Younger C, et al: Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 93:11471152, 2001
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|